Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2012; 18(42): 6060-6069
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6060
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6060
Table 2 Sustained virological response rates in phase III clinical trials with hepatitis C virus protease inhibitor-based regimens in treatment-naïve and treatment-experienced patients
| Name of trial | SVR | |
| Naïve patients - Treatment group | ||
| SPRINT-2 | ||
| BOC/RGT | 63% | |
| BOC44/PR48 | 66% | |
| PR48 | 38% | |
| ADVANCE | ||
| T12PR | 75% | |
| T8PR | 69% | |
| PR | 44% | |
| ILLUMINATE | ||
| T12PR24 (eRVR+) | 92% | |
| T12PR48 (eRVR+) | 87% | |
| T12PR48 (eRVR-) | 64% | |
| < 20 wk | 23% | |
| Treatment-experienced patients - Treatment group | ||
| RESPOND-2 | ||
| Prior relapsers | PR48 | 29% |
| BOC/RGT | 69% | |
| BOC44/PR48 | 75% | |
| Prior partial responders | PR48 | 7% |
| BOC/RGT | 40% | |
| BOC44/PR48 | 52% | |
| REALIZE | ||
| Prior relapsers | PR48 | 24% |
| LIT12PR48 | 88% | |
| T12PR48 | 83% | |
| Prior partial responders | PR48 | 15% |
| LIT12PR48 | 54% | |
| T12PR48 | 59% | |
| Prior null responders | PR48 | 5% |
| LIT12PR48 | 33% | |
| T12PR48 | 29% | |
- Citation: Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18(42): 6060-6069
- URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6060.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6060